NASDAQ: SNWV · Industrial Applications and Services · 4 alerts · CIK 1417663
Share price
$1.81Close, Nov 16
Market cap
$15.6M
Shares outstanding
8.6MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sanuwave Health, Inc. filings on SEC EDGAR ↗
SANUWAVE Health reported Q3 2026 revenue of $8.6 million, a 24% decrease year-over-year, primarily driven by a significant drop in Ultramist system sales. The company posted a net loss of $1.4 million for the quarter, compared to net income of $9.7 million in the prior year, which had benefited from one-time gains. Management attributed the performance to market uncertainty surrounding proposed CMS rule changes affecting wound care reimbursement.
Term
Q3 2026
“Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways. The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”
SANUWAVE Health reported a net operating loss of $2.5 million for the nine months ended September 30, 2026, compared to an operating income of $2.9 million in the prior year period. Total revenue decreased to $27.9 million from $30.7 million, while operating expenses increased primarily due to higher research and development and selling costs.
Sanuwave Health Debt Financing Update with JPMorgan Chase Bank, N.A.
SANUWAVE Health entered into an amendment and waiver to its existing credit agreement with JPMorgan Chase Bank. The lenders waived a default related to the fixed charge coverage ratio for the period ending September 30, 2026, while tightening restrictions on acquisitions, stock repurchases, and permitted indebtedness.